According to Fortune Business Insights, the hereditary angioedema treatment market was valued at USD 5.59 billion in 2024. The market is projected to grow from USD 6.53 billion in 2025 to USD 19.68 billion by 2032, exhibiting a CAGR of 17.1% during 2025-2032. In 2024, North America dominated the hereditary angioedema treatment market with a market share of 93.05%.